Derived from the Greek “probiotic,” meaning “for life,” probiotics are live microorganisms that benefit health when consumed in the right amounts. Prebiotics, on the other hand, support probiotic bacteria growth in the body. Synbiotics, a combination of both, play a therapeutic role in maintaining a healthy gastrointestinal tract. Notably, they reduce inflammatory markers like HSCRP, IL-6, and TNF. This makes them effective in managing conditions like uremic pruritus and Kyrle’s disease (KD), particularly in the context of chronic kidney disease (CKD) and uraemia. Synbiotics thus significantly enhance well-being through their profound gut health impact.

Enzotien, a unique blend of proteolytic enzymes and low-dose protein supplements, effectively tackles protein energy malnutrition in economically disadvantaged end-stage renal disease (ESRD) patients. By enhancing protein breakdown and assimilation, Enzotien matches the nutritional and anti-inflammatory benefits of high-dose protein intake. This innovative combination excels at facilitating the efficient breakdown, assimilation, and absorption of proteins with an impressive PDCAAS value >1. This innovative approach can serve as a viable, cost-effective solution in resource-limited settings, promising to alleviate protein energy malnutrition and accelerate recovery, potentially shortening the healing process by 18 months for ESRD patients undergoing hemodialysis.